1,5-Anhydro-D-Fructose Reductase (AKR1CL2) Antibody
52€ (10 µg)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
1,5-Anhydro-D-Fructose Reductase (AKR1CL2) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx014170
tested applications
ELISA, WB
Description
Rabbit polyclonal antibody against AKR1CL2 protein. Immunogen region is Internal.
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | 1,5-Anhydro-D-Fructose Reductase (AKR1CL2) |
| Host | Rabbit |
| Reactivity | Human |
| Recommended Dilution | WB: 1/500 - 1/3000, ELISA: 1/10000. Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Polyclonal |
| Conjugation | Unconjugated |
| Isotype | IgG |
| Purification | Purified from rabbit antiserum by affinity chromatography using epitope-specific immunogen. |
| Size 1 | 10 µg |
| Size 2 | 100 µg |
| Size 3 | 200 µg |
| Size 4 | 300 µg |
| Size 5 | 1 mg |
| Form | Liquid |
| Tested Applications | ELISA, WB |
| Buffer | PBS (without Mg<sup>2+</sup> and Ca<sup>2+</sup>), pH 7.4, 150 mM NaCl, 0.02% sodium azide, 50% glycerol. |
| Availability | Shipped within 5-10 working days. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| UniProt ID | Q96JD6 |
| Alias | AKR1E2,AKR1CL2,AKRDC1 |
| Background | Antibody anti-AKR1E2 |
| Status | RUO |
| Note | Concentration: 1 mg/ml - |
Descripción
AKR1E2 is a less characterized member of the aldo-keto reductase superfamily but is known to catalyze the reduction of various aldehydes and ketones, contributing to cellular detoxification and redox balance. AKR1E2 has a broad substrate specificity, metabolizing reactive aldehydes such as those derived from lipid peroxidation (4-HNE) and environmental toxins. Its enzymatic activity protects cells from oxidative stress and damage caused by reactive carbonyl species (RCS), linking it to cellular defense mechanisms. While its tissue-specific expression and physiological roles are still being elucidated, AKR1E2 likely plays a role in liver and kidney detoxification processes. Emerging evidence suggests its involvement in redox regulation and energy metabolism under stress conditions. Dysregulation of AKR1E2 may contribute to oxidative stress-associated diseases, including neurodegeneration, cardiovascular disease, and cancer, where impaired detoxification exacerbates cellular damage. Further studies are needed to clarify its unique functions and therapeutic potential.
